US › Healthcare

Rocket Pharmaceuticals Inc (RCKT)

US · Healthcare · Biotechnology

$2.38-2.05%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$123.2M

EPS

$-0.15

EPS estimate

$0.28

EPS came in at -0.15 against a street estimate of 0.28 — a miss of 153.6%.

Key statistics

Market cap

$261.8M

Forward P/E

0.0

P/B

0.72

Book value

$3.37

EPS (TTM)

$-0.17

52-week high

$5.45

52-week low

$2.17

50-day MA

$2.87

200-day MA

$3.43

Beta

0.49

Analyst view

Analysts rate Rocket Pharmaceuticals Inc a buy (7 buy, 6 hold, 1 sell out of 14) with an average price target of $8.58.

Shareholding

Insiders

3.18%

Institutions

87.94%

Largest institutional holders

Fund	Stake
RTW INVESTMENTS, LLC	16.11%
BlackRock Inc	9.04%
Vanguard Portfolio Management, LLC	5.29%
Citigroup Inc	4.43%
Marshall Wace Asset Management Ltd	3.67%
Millennium Management LLC	3.64%
Newtyn Management LLC	3.64%
Maverick Capital Ltd	3.57%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rocket Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.